ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1150

Increased ISG15 Expression in Peripheral Blood from Patients with Positive Dermatomyositis Related Specific Autoantibodies
Abstract Number: 1151

Clinical Characterization and Recurrence Prediction Model for Immune-Mediated Necrotizing Myopathy
Abstract Number: 1152

Nailfold Videocapillaroscopy Abnormalities in Different Autoimmune Inflammatory Myopathy Subsets
Abstract Number: 1153

Increased Prevalence of Myositis Specific and Associated Autoantibodies in Patients with Interstitial Lung Disease of Unknown Etiology
Abstract Number: 1154

Comparative Transcriptome Analysis of Murine Model and Human Samples in Anti-Melanoma Differentiation Associated Gene 5 Antibody-positive Rapidly Progressive Interstitial Lung Disease
Abstract Number: 1155

Stratification of Cancer Risk in Idiopathic Inflammatory Myopathies. Application of the IMACS Guidelines to Enhance Screening
Abstract Number: 1156

Prevalence and Impact of Fibromyalgia in Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 1157

Reduced Statin Use in Patients with Autoimmune Myopathies and Systemic Lupus Erythematosus Compared to Rheumatoid Arthritis and Non-Inflammatory Diseases
Abstract Number: 1158

Microvascular Differences Between Cancer and Non-cancer Anti-transcriptional Intermediary Factor 1 Gamma Antibody (anti-TIF1-γ) Associated Dermatomyositis Patients
Abstract Number: 1159

Anti-synthetase Syndrome (ASSD) Related Interstitial Lung Disease (ILD) in Comparison to Non-ASSD Related ILDs: Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database
Abstract Number: 1160

Short Form-36 Psychometric Properties in Idiopathic Inflammatory Myopathies: Reliability, Validity and Responsiveness
Abstract Number: 1161

Characterization of the Clinical Presentation of Idiopathic Inflammatory Myopathies According to the Profile of Specific Autoantibodies with Multiple Positivity
Abstract Number: 1162

Evaluating the Efficacy of Rituximab in the Treatment of Refractory Adult Idiopathic Inflammatory Myositis Using Total Improvement Score: Data from a Real-World Multi-Centre Registry in the United Kingdom
Abstract Number: 1163

Characteristics of Interstitial Lung Disease Progressors in an Antisynthetase Autoantibody-Positive Population
Abstract Number: 1164

IVIG Treatment Duration in Immune-mediated Necrotizing Myopathy and a Possible Association of Vacuolar Changes with Black/African American Female Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].